NCT05066607 2024-03-06
IsAMYP
Intergroupe Francophone du Myelome
Phase 2 Unknown
Clinical Trials
17 trialsNCT01754402 2024-02-20
Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
Duke University
Phase 1/2 Unknown
NCT05478993 2024-01-31
SPODUMENE
Peking University People's Hospital
Phase 2 Unknown
NCT05378971 2023-10-04
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
LanZhou University
Phase NA Unknown
NCT04941937 2023-02-27
Selinexor in Combination With Immunomodulator ļ¼Thalidomide/Pomalidomide/Lenalidomideļ¼in RRMM
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT05432414 2023-01-31
PVd Versus Vd in NDMM Patients With RI
RenJi Hospital
Phase 2 Unknown
NCT05509374 2022-08-22
KMM2002
Samsung Medical Center
Phase 2 Unknown
NCT03113942 2022-03-31
SPACE
Kirby Institute
Phase 2 Unknown
NCT05298683 2022-03-28
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
Phase 2 Unknown
NCT05236621 2022-02-11
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT04762745 2021-02-21
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Unknown
NCT03015922 2020-01-22
MUKeleven
University of Leeds
Phase 1 Unknown
NCT03601624 2018-11-14
MM-POM-2018
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Phase 2 Unknown
NCT02158702 2018-05-17
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
National University Hospital, Singapore
Phase 2 Unknown
NCT02916420 2016-11-02
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT01541332 2016-03-10
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
Phase 1/2 Unknown